Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib/II trial

• Published in: Journal of hematology and oncology Vol. 18; no. 1; pp. 15 - 10
• Main Authors: Chen, Gang, Sun, Dong-Chen, Ba, Yi, Zhang, Ya-Xiong, Zhou, Ting, Zhao, Yuan-Yuan, Zhao, Hong-Yun, Fang, Wen-Feng, Huang, Yan, Wang, Zhen, Deng, Chao, Hu, De-Sheng, Wang, Wei, Lin, Jin-Guan, Li, Gui-Ling, Luo, Su-Xia, Fu, Zhi-Chao, Zhu, Hai-Sheng, Wang, Hui-Li, Cai, Sheng-Li, Kang, Xiao-Qiang, Zhang, Li, Yang, Yun-Peng
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 07.02.2025; BioMed Central; BMC
• Subjects: Adult; Adverse events; Aged; Alanine transaminase; Antibodies; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; Antigens, CD - immunology; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Antitumor activity; Aspartate; Aspartate aminotransferase; Biomarkers; Cancer; Carcinoma; CD223 antigen; Combination therapy; Consent; Disease control; Esophageal cancer; FDA approval; Female; Humans; Hyponatremia; Immune Checkpoint Inhibitors - adverse effects; Immune Checkpoint Inhibitors - therapeutic use; Immunotherapy; Lung cancer; Lymphocyte Activation Gene 3 Protein; Lymphocytes; Male; Medical research; Medicine, Experimental; Melanoma; Middle Aged; Nasopharyngeal carcinoma; Nasopharyngeal Carcinoma - drug therapy; Nasopharyngeal Carcinoma - pathology; Nasopharyngeal Neoplasms - drug therapy; Neoplasms - drug therapy; Patients; PD-1 protein; PD-L1 protein; Product development; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Solid tumors; Squamous cell carcinoma; Toxicity; Tumors; Viral antibodies

Open-label phase Ib/II study to investigate the safety and efficacy of LBL-007, an anti-LAG-3 antibody, plus toripalimab, an anti-PD-1 antibody, in patients with previously treated advanced nasopharyngeal carcinoma (NPC) and other solid tumors. Patients with advanced tumors refractory to prior stand...